Foundayo vs Zepbound: Lilly's New Pill vs the Injection It Might Replace

Foundayo vs Zepbound at a glance

Efficacy: the gap is real

Zepbound's dual GIP/GLP-1 mechanism produced approximately 21% average body weight loss at the 15 mg dose in the SURMOUNT program — still the class leader among approved drugs. Orforglipron's Phase 3 ATTAIN results showed roughly 12% at the top dose. That is a nearly 2x difference: on a 220 lb patient, Zepbound averages about 46 lbs lost vs about 26 lbs on Foundayo.

Foundayo still outperforms the older oral options: Rybelsus delivers ~5-8% and the Wegovy pill about 15%. Read our orforglipron guide for full trial details.

Who each drug is for

Choose Zepbound if: you want maximum weight loss, you have significant weight to lose, or you have type 2 diabetes needing aggressive metabolic control. Choose Foundayo if: you refuse injections, you travel constantly, or you only need moderate loss and value convenience over efficacy.

A likely real-world pattern: patients start on Zepbound, reach goal weight, then transition to the easier daily pill for maintenance — though some weight regain is plausible given the efficacy gap.

Side effects comparison

Both share the GLP-1 class profile: nausea, vomiting, diarrhea, and constipation during titration, mostly mild-to-moderate. Orforglipron's GI discontinuation rates in Phase 3 were comparable to other oral GLP-1s. Zepbound's weekly dosing means fewer dosing events but stronger peak effects early in each dose increase.

Frequently asked questions

Is Foundayo as effective as Zepbound?

No. In trials, oral orforglipron (Foundayo) produced about 12% average body weight loss at the highest dose, while injectable tirzepatide (Zepbound) produces around 21%. Zepbound remains significantly more effective, but Foundayo is needle-free.

When will Foundayo be available?

Orforglipron is in Phase 3 trials, and Lilly has signaled it will file for FDA approval as the data completes. A launch is widely expected in the near term; Lilly is already building commercial capacity.

Is Foundayo the same company as Zepbound?

Yes. Both are Eli Lilly products. Zepbound is injectable tirzepatide (GIP/GLP-1 dual agonist); Foundayo is oral orforglipron (GLP-1 only). Lilly positions Foundayo as the convenient option and Zepbound as the maximum-efficacy option.

Can I switch from Zepbound to Foundayo?

That will be a real option once Foundayo launches — patients who reach their goal on Zepbound may maintain on the easier pill, though some regain is likely given the efficacy gap. Discuss with your prescriber.

What is cheaper than Zepbound today?

Compounded tirzepatide through licensed US telehealth programs costs $199 to $299/month versus roughly $1,050 retail for Zepbound. Same molecule, fraction of the price.

Bottom line

Zepbound is the efficacy king; Foundayo will be the convenience king. If you want tirzepatide-level results at a price you can afford now, licensed compounded-tirzepatide telehealth programs start around $199/month — no waiting for a pill launch.